Extract from M&A Insights

The below story was originally featured in our daily M&A Insights Newsletter. Selected stories, including this one, are posted to our website with a few weeks of delay.
Ultimovacs to apply for listing on Oslo Stock Exchange
May 21, 2019

The Norwegian-based pharmaceutical firm Ultimovacs has applied for listing on Oslo Stock Exchange. Ultimovacs is developing the world’s first universal cancer vaccine. The IPO pre-money values the firm at NOK 500m and Ultimovac expects to raise NOK 370m. In 2018, Ultimovac reported no turnover and EBIT of NOK 56.5m.

ⓘ This story was originally featured in our daily M&A Insights newsletter.
Our insights have been covered by: